Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1987 1
1992 1
1996 2
1998 2
1999 1
2000 3
2001 2
2002 2
2003 1
2004 4
2005 5
2006 4
2007 6
2008 4
2009 4
2010 5
2011 6
2012 8
2013 2
2014 4
2015 6
2016 4
2017 3
2018 1
2020 3
2021 5
2022 1
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

84 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: Bulhoes-Carvalho
Page 1
Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium.
El Zarif T, Nassar AH, Adib E, Fitzgerald BG, Huang J, Mouhieddine TH, Rubinstein PG, Nonato T, McKay RR, Li M, Mittra A, Owen DH, Baiocchi RA, Lorentsen M, Dittus C, Dizman N, Falohun A, Abdel-Wahab N, Diab A, Bankapur A, Reed A, Kim C, Arora A, Shah NJ, El-Am E, Kozaily E, Abdallah W, Al-Hader A, Abu Ghazal B, Saeed A, Drolen C, Lechner MG, Drakaki A, Baena J, Nebhan CA, Haykal T, Morse MA, Cortellini A, Pinato DJ, Dalla Pria A, Hall E, Bakalov V, Bahary N, Rajkumar A, Mangla A, Shah V, Singh P, Aboubakar Nana F, Lopetegui-Lia N, Dima D, Dobbs RW, Funchain P, Saleem R, Woodford R, Long GV, Menzies AM, Genova C, Barletta G, Puri S, Florou V, Idossa D, Saponara M, Queirolo P, Lamberti G, Addeo A, Bersanelli M, Freeman D, Xie W, Reid EG, Chiao EY, Sharon E, Johnson DB, Ramaswami R, Bower M, Emu B, Marron TU, Choueiri TK, Baden LR, Lurain K, Sonpavde GP, Naqash AR. El Zarif T, et al. Among authors: el am e. J Clin Oncol. 2023 Jul 20;41(21):3712-3723. doi: 10.1200/JCO.22.02459. Epub 2023 May 16. J Clin Oncol. 2023. PMID: 37192435
Cardiotoxicities of Novel Therapies in Hematological Malignancies: Monoclonal Antibodies and Enzyme Inhibitors.
Prathivadhi-Bhayankaram S, Abbasi MA, Ismayl M, Marar RI, Al-Abcha A, El-Am E, Ahmad A, Acevedo AD, Ellauzi R, Villarraga H, Paludo J, Anavekar N. Prathivadhi-Bhayankaram S, et al. Among authors: el am e. Curr Probl Cardiol. 2023 Aug;48(8):101757. doi: 10.1016/j.cpcardiol.2023.101757. Epub 2023 Apr 23. Curr Probl Cardiol. 2023. PMID: 37094764 Review.
Yet, they also elicit severe immune-mediated reactions as biological agents that require careful monitoring. Cardiovascular effects include cardiomyopathy, ventricular dysfunction, cardiac arrest, and acute coronary syndrome. ...
Yet, they also elicit severe immune-mediated reactions as biological agents that require careful monitoring. Cardiovascular effects i …
Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors.
El Zarif T, Nassar AH, Pond GR, Zhuang TZ, Master V, Nazha B, Niglio S, Simon N, Hahn AW, Pettaway CA, Tu SM, Abdel-Wahab N, Velev M, Flippot R, Buti S, Maruzzo M, Mittra A, Gheeya J, Yang Y, Rodriguez PA, Castellano D, de Velasco G, Roviello G, Antonuzzo L, McKay RR, Vincenzi B, Cortellini A, Hui G, Drakaki A, Glover M, Khaki AR, El-Am E, Adra N, Mouhieddine TH, Patel V, Piedra A, Gernone A, Davis NB, Matthews H, Harrison MR, Kanesvaran R, Giudice GC, Barata P, Farolfi A, Lee JL, Milowsky MI, Stahlfeld C, Appleman L, Kim JW, Freeman D, Choueiri TK, Spiess PE, Necchi A, Apolo AB, Sonpavde GP. El Zarif T, et al. Among authors: el am e. J Natl Cancer Inst. 2023 Dec 6;115(12):1605-1615. doi: 10.1093/jnci/djad155. J Natl Cancer Inst. 2023. PMID: 37563779
Neuroprotective and neurorestorative potential of propargylamine derivatives in ageing: focus on mitochondrial targets.
Bar-Am O, Amit T, Youdim MB, Weinreb O. Bar-Am O, et al. J Neural Transm (Vienna). 2016 Feb;123(2):125-35. doi: 10.1007/s00702-015-1395-3. Epub 2015 Apr 10. J Neural Transm (Vienna). 2016. PMID: 25859841 Review.
This review addresses several aspects of the neuroprotective effects of propargylamine derivatives (e.g., the monoamine oxidase-B inhibitors, selegiline and rasagiline and the multifunctional drugs, ladostigil, M30 and VAR10303) in ageing with a special focus on mitochondr …
This review addresses several aspects of the neuroprotective effects of propargylamine derivatives (e.g., the monoamine oxidase-B inh …
Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition.
Youdim MB, Bar Am O, Yogev-Falach M, Weinreb O, Maruyama W, Naoi M, Amit T. Youdim MB, et al. Among authors: bar am o. J Neurosci Res. 2005 Jan 1-15;79(1-2):172-9. doi: 10.1002/jnr.20350. J Neurosci Res. 2005. PMID: 15573406 Review.
Rasagiline (N-propargyl-1R-aminoindan) is a novel, highly potent irreversible monoamine oxidase (MAO) B inhibitor anti-Parkinson drug. Unlike selegiline, it is not derived from amphetamine, and is not metabolized to neurotoxic L-methamphetamine derivative. ...
Rasagiline (N-propargyl-1R-aminoindan) is a novel, highly potent irreversible monoamine oxidase (MAO) B inhibitor anti-Parkinson drug …
The neuroprotective mechanism of action of the multimodal drug ladostigil.
Weinreb O, Amit T, Bar-Am O, Yogev-Falach M, Youdim MB. Weinreb O, et al. Among authors: bar am o. Front Biosci. 2008 May 1;13:5131-7. doi: 10.2741/3069. Front Biosci. 2008. PMID: 18508575 Review.
The recent therapeutic approach in which drug candidates are designed to possess diverse pharmacological properties and act on multiple targets has stimulated the development of the multimodal drug, ladostigil (TV3326) ((N-propargyl-(3R) aminoindan-5yl)-ethyl methyl …
The recent therapeutic approach in which drug candidates are designed to possess diverse pharmacological properties and act on multip …
Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer's disease drugs.
Weinreb O, Mandel S, Bar-Am O, Yogev-Falach M, Avramovich-Tirosh Y, Amit T, Youdim MB. Weinreb O, et al. Among authors: bar am o. Neurotherapeutics. 2009 Jan;6(1):163-74. doi: 10.1016/j.nurt.2008.10.030. Neurotherapeutics. 2009. PMID: 19110207 Free PMC article. Review.
The recent therapeutic approach in which drug candidates are designed to possess diverse pharmacological properties and act on multiple targets has stimulated the development of the multimodal drugs, ladostigil (TV3326) [(N-propargyl-(3R) aminoindan-5yl)-ethyl methyl carba …
The recent therapeutic approach in which drug candidates are designed to possess diverse pharmacological properties and act on multip …
Novel multifunctional anti-Alzheimer drugs with various CNS neurotransmitter targets and neuroprotective moieties.
Van der Schyf CJ, Mandel S, Geldenhuys WJ, Amit T, Avramovich Y, Zheng H, Fridkin M, Gal S, Weinreb O, Bar Am O, Sagi Y, Youdim MB. Van der Schyf CJ, et al. Among authors: bar am o. Curr Alzheimer Res. 2007 Dec;4(5):522-36. doi: 10.2174/156720507783018226. Curr Alzheimer Res. 2007. PMID: 18220515 Review.
Traditionally, drug design programs are focused on optimizing the specificity of lead compounds against a carefully selected drug target. ...An emerging concept is the design of drug ligands that modulate multiple drug targets identified for a particul …
Traditionally, drug design programs are focused on optimizing the specificity of lead compounds against a carefully selected drug …
The neuroprotective mechanism of 1-(R)-aminoindan, the major metabolite of the anti-parkinsonian drug rasagiline.
Bar-Am O, Weinreb O, Amit T, Youdim MB. Bar-Am O, et al. J Neurochem. 2010 Mar;112(5):1131-7. doi: 10.1111/j.1471-4159.2009.06542.x. Epub 2009 Dec 10. J Neurochem. 2010. PMID: 20002521 Free article. Review.
The anti-parkinsonian drug, rasagiline [N-propargyl-1-(R)-aminoindan; Azilect(R)], is a secondary cyclic benzylamine and indane derivative, which provides irreversible, potent monoamine oxidase-B (MAO-B) inhibition and possesses neuroprotective and neurorestorative activit …
The anti-parkinsonian drug, rasagiline [N-propargyl-1-(R)-aminoindan; Azilect(R)], is a secondary cyclic benzylamine and indane deriv …
84 results